Neuroscience Bulletin

, Volume 32, Issue 6, pp 591–596 | Cite as

Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease

  • Xiaoli Pan
  • Zhichun Chen
  • Guoqiang Fei
  • Shumei Pan
  • Weiqi Bao
  • Shuhua Ren
  • Yihui Guan
  • Chunjiu ZhongEmail author


To date, we still lack disease-modifying therapies for Alzheimer’s disease (AD). Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with β-amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improvement as assayed by the Mini-Mental Status Examination (MMSE) with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain compared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Our study provides new insight to the development of disease-modifying therapy.


Alzheimer’s disease Therapy Benfotiamine PiB-PET Amyloid deposition 



This work was supported by the Key Fund for Developing New Drugs from the Ministry of Science and Technology of China (2014ZX09101005-005), the National Natural Science Foundation of China (81071019), the National Key Basic Research Program of China (2011CBA00400), the Natural Science Foundation of Shanghai Municipality, China (13JC1401500), and the Fund for Medical Emerging Cutting-Edge Technology in Shanghai of China (SHDC12012114). We thank Dr. Mu-ming Poo (Institute of Neuroscience, State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) for his valuable insight and critique of the article. We also thank Dr. Alexandra H. Marshal (Department of Laboratory Medicine and Pathobiology, St. Michael’s Hospital, University of Toronto) for her careful editing of the article. We gratefully acknowledge all of the participants for their contributions to this study.

Supplementary material

12264_2016_67_MOESM1_ESM.pdf (125 kb)
Supplementary material 1 (PDF 125 kb)


  1. 1.
    Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372: 216–223.CrossRefPubMedGoogle Scholar
  2. 2.
    Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014, 370: 322–333.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014, 370: 311–321.CrossRefPubMedGoogle Scholar
  4. 4.
    Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013, 369: 341–350.CrossRefPubMedGoogle Scholar
  5. 5.
    Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68: 501–508.CrossRefPubMedGoogle Scholar
  6. 6.
    Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996, 334: 752–758.CrossRefPubMedGoogle Scholar
  7. 7.
    Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol 1988, 45: 836–840.CrossRefPubMedGoogle Scholar
  8. 8.
    Mastrogiacoma F, Bettendorff L, Grisar T, Kish SJ. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer’s disease. Ann Neurol 1996, 39: 585–591.CrossRefPubMedGoogle Scholar
  9. 9.
    Heroux M, Raghavendra Rao VL, Lavoie J, Richardson JS, Butterworth RF. Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer’s disease. Metab Brain Dis 1996, 11: 81–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Pan X, Fei G, Lu J, Jin L, Pan S, Chen Z, et al. Measurement of blood thiamine metabolites for Alzheimer’s disease diagnosis. EBioMedicine 2016, 3: 155–162.CrossRefPubMedGoogle Scholar
  11. 11.
    Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pechman D, et al. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer’s mouse model. Neurobiol Aging 2009, 30: 1587–1600.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang D, Hazell AS. Microglial activation is a major contributor to neurologic dysfunction in thiamine deficiency. Biochem Biophys Res Commun 2010, 402: 123–128.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhao J, Sun X, Yu Z, Pan X, Gu F, Chen J, et al. Exposure to pyrithiamine increases beta-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain. Neurotox Res 2011, 19: 575–583.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang Q, Yang G, Li W, Fan Z, Sun A, Luo J, et al. Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides. Neurobiol Aging 2011, 32: 42–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013, 108: 21–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9: 294–299.CrossRefPubMedGoogle Scholar
  17. 17.
    Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 2010, 61: 482–488.CrossRefPubMedGoogle Scholar
  18. 18.
    Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133: 1342–1351.CrossRefPubMedGoogle Scholar
  19. 19.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011, 7: 263–269.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003, 46: 2740–2754.CrossRefPubMedGoogle Scholar
  21. 21.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004, 55: 306–319.CrossRefPubMedGoogle Scholar
  22. 22.
    Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 2007, 48: 547–552.CrossRefPubMedGoogle Scholar
  23. 23.
    Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis 2005, 7: 63–80.PubMedGoogle Scholar
  24. 24.
    Blass JP, Gleason P, Brush D, DiPonte P, Thaler H. Thiamine and Alzheimer’s disease. A pilot study. Arch Neurol 1988, 45: 833–835.CrossRefPubMedGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer Science+Business Media Singapore 2016

Authors and Affiliations

  • Xiaoli Pan
    • 1
  • Zhichun Chen
    • 1
  • Guoqiang Fei
    • 1
  • Shumei Pan
    • 1
  • Weiqi Bao
    • 2
  • Shuhua Ren
    • 2
  • Yihui Guan
    • 2
  • Chunjiu Zhong
    • 1
    Email author
  1. 1.Department of Neurology, Zhongshan Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain ScienceFudan UniversityShanghaiChina
  2. 2.PET Center, Huashan HospitalFudan UniversityShanghaiChina

Personalised recommendations